https://orcid.org/0000-0001-8326-7867
References
- Schatman ME. The American chronic pain crisis and the media: about time to get it right? J Pain Res. 2015;8:885–887. doi:10.2147/JPR.S102090
- Raffa RB, Pergolizzi JV Jr, LeQuang JA, et al. The fentanyl family: a distinguished medical history tainted by abuse. J Clin Pharm Ther. 2018;43(1):154–158. doi:10.1111/jcpt.12640
- Drug Enforcement Administration. Counterfeit Prescription Pills Containing Fentanyls: A Global Threat. DEA Intelligence Brief; 2016. Available from: https://www.dea.gov/docs/Counterfeit%20Prescription%20Pills.pdf.
- Ahmad FB, Escobedo LA, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts; 2018. Available from: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdosedata.htm. Accessed June 26, 2020.
- Fallon K. Personal communication, February, 2020
- Analogue act. 1988. (DEA) Title 21 Section 813. U.S. DEA.
- Bettinger JJ, Trotta ND, Fudin J, Wegrzyn EL, Schatman ME. Understanding the differences between pharmaceutical and illicit fentanyl and their analogues could save the opioid crisis. Pract Pain Manage. 2018;8(5):59–67.
- US Department of Justice, Drug Enforcement Administration, Strategic Intelligence Section. 2018 national drug threat assessment report; 2018. Available from: https://www.dea.gov/sites/default/files/2018-11/DIR-0328%202018%20NDTA%20final%20low%20resolution.pdf.
- Singh VM, Browne T, Montgomery J. The emerging role of toxic adulterants in street drugs in the US illicit opioid crisis. Public Health Rep. 2020;135(1):6–100. doi:10.1177/0033354919887741
- Sofalvi S, Lavins ES, Brooker IT, et al. Unique structural/stereo-isomer and isobar analysis of novel fentanyl analogues in postmortem and DUID whole blood by UHPLC-MS-MS. J Anal Toxicol. 2019;43(9):673–687. doi:10.1093/jat/bkz056
- Volkow ND, McLellan AT. Opioid abuse in chronic pain—misconceptions and mitigation strategies. N Eng J Med. 2016;374(13):1253–1263. doi:10.1056/NEJMra1507771